Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.

BASEL, Switzerland and LONDON, United Kingdom, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Nancy Valente, M.D. as an independent member of the company's Board of Directors. Dr. Valente is a renowned expert in hematology and oncology drug development with over 20 years of experience leading global development programs at Genentech/Roche and other leading pharmaceutical companies involving novel first-in-class molecules. In addition to her Board appointment, Dr. Valente will chair the Board's Nominating and Corporate Governance Committee and be a member of the Audit Committee.

Nancy Valente, M.D. Joins Myovant Sciences' Board of Directors

Myovant Sciences (MYOV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Myovant Sciences (MYOV) Rating Upgrade to Buy

PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences, a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), today announced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5. SP-101, an investigational novel recombinant adeno-associated virus (AAV) gene therapy selected for its tropism to human airway epithelia, is being developed for inhalation in patients with CF who do not benefit from treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators, which is approximately 20% of all patients with CF.

Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference

Tucked in its Q2 earnings release, Myovant Sciences Ltd (NYSE: MYOV) said that Pfizer Inc (NYSE: PFE) has notified its option decision for international rights to relugolix in oncology. Pfizer declined its option based on its assessment of its current strategic investment priorities in international markets.

Why Did Myovant Sciences Shares Fall Despite Q2 Earnings Beat?

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q2 2021 Results - Earnings Call Transcript

BASEL, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced financial results for the second quarter of fiscal year 2021 and other corporate updates.

Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the presentation of new data from clinical studies of its once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in premenopausal women with uterine fibroids and in women with endometriosis pain (an investigational use). The data are being presented in oral sessions during the American Society for Reproductive Medicine (ASRM) 2021 Congress.

Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

BASEL, Switzerland, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter 2021, ended September 30, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on October 26, 2021.

Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on October 26, 2021

RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia

Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences Presents Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Showing No Significant Effects on Blood Pressure or Heart Rate

Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate

Pfizer

Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.

Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA

BASEL, Switzerland and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022 for this sNDA under the Prescription Drug User Fee Act (PDUFA).

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences to Present New Data at the Virtual 2021 Annual Meeting of the American Urological Association

Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association

BASEL, Switzerland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time in addition to participating in small group investor meetings.

Myovant Sciences to Participate in the 2021 Baird Global Healthcare Conference

BASEL, Switzerland, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc.  Mr. Mehra will succeed Frank Karbe, who has decided to pursue other opportunities and will serve in an advisory capacity to support Mr. Mehra's transition.   Beginning September 7, 2021, Mr. Mehra will lead Myovant's finance, alliance partnerships, and business development functions and will be a member of Myovant's Executive Committee, reporting to Dave Marek, Myovant's Chief Executive Officer.

Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer

Second-quarter earnings results were a little bit disappointing.

Here's Why Myovant Sciences Stock Is Falling Today

Myovant Sciences Ltd. (MYOV) CEO Dave Marek on Q1 2021 Results - Earnings Call Transcript

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -219.05% and -32.89%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences (MYOV) Reports Q1 Loss, Misses Revenue Estimates

Shares of Myovant Sciences (NYSE:MYOV) rose 1.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 81.08% year over year to ($0.67), which missed the estimate of ($0.33).

Recap: Myovant Sciences Q1 Earnings

BASEL, Switzerland, July 28, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced corporate updates and financial results for the first quarter of fiscal year 2021.

Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates

Myovant Sciences (MYOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myovant Sciences (MYOV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE: MYOV) Ryeqo (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symptoms of uterine fibroids in adult women. The approval is based on safety and efficacy data from the Phase 3 LIBERTY program, which consisted of two replicate, 24-week, multinational clinical studies (LIBERTY 1 and LIBERTY 2), a one-year extension study, and supportive bone mineral density data from a randomized withdrawal study.

Europe OK's Myovant's Relugolix Combo Therapy For Uterine Fibroids

BASEL, Switzerland, July 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Commission (EC) has approved the marketing authorization application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use. The EC decision is valid in all 27 member states of the European Union, as well as Iceland, Norway, and Liechtenstein.

Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids

BASEL, Switzerland, July 14, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter 2021, ended June 30, 2021. The webcast and conference call will be held at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on July 28, 2021.

News for Myovant Sciences Stock (MYOV)